Our study identified that, irrespective of the PD-L1 expression level, ICI carried a higher risk of all-grades and grades 3–5 CIP compared to chemotherapy, particularly in patients with elevated PD-L1 expression. The gene discussed is CD274; the disease is hereditary sensory and autonomic neuropathy.